Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 5, 2018

Study Completion Date

June 30, 2027

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

carfilzomib

DRUG

Lenalidomide

DRUG

Dexamethasone

DRUG

Melphalan

Trial Locations (16)

Unknown

Hospital Clínic de Barcelona, Barcelona

Hospital Universitari Germans Trias i Pujol, Barcelona

Hospital Clínico San Carlos, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitario Morales Meseguer, Murcia

Hospital Universitario Central de Asturias, Oviedo

Clínica Universidad de Navarra, Pamplona

Hospital de Son Llàtzer, Plama de Mallorca

Hospital Universitario de Salamanca, Salamanca

Hospital Universitario de Canarias, Santa Cruz de Tenerife

Hospital Universitario Reina Sofía, Seville

Hospital Universitario Virgen del Rocío, Seville

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario Doctor Peset, Valencia

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

PETHEMA Foundation

OTHER

NCT02415413 - Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter